MB-106 Shows Continued Activity in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
The FDA has granted priority review to the supplemental new drug application seeking the approval of ivosidenib for the treatment of patients with IDH1-mutated, relapsed/refractory myelodysplastic syndrome.
Nausheen Ahmed, MD, explains the rationale for examining real-world outcomes observed with the use of brexu-cel in the treatment of patients with relapsed/refractory mantle cell lymphoma, details the key efficacy and safety findings from the overall population and different subgroups, and discusses what will be gained with longer follow-up of the study.
The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor.